ID
45513
Description
Principal Investigator: Sami N. Malek, MD, University of Michigan Department of Internal Medicine, Division of Hematology-Oncology, Ann Arbor, MI, USA MeSH: Lymphoma, Follicular,Lymphoma, Non-Hodgkin https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000729 A cohort of follicular lymphoma cases had tumor cells purified from tissue samples after informed consent using flow cytometry. DNA was extracted from the cells, and samples were subjected to solution-based exome capture using the Illumina TruSeq Exome Enrichment Kit and the Illumina HiSeq 2000 platform.
Lien
Mots-clés
Versions (1)
- 13.12.22 13.12.22 - Simon Heim
Détendeur de droits
Sami N. Malek, MD, University of Michigan Department of Internal Medicine, Division of Hematology-Oncology, Ann Arbor, MI, USA
Téléchargé le
13. Dezember 2022
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
dbGaP phs000729 Follicular Lymphoma 2013 - Malek
Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type of cancer, and method for tumor and normal cell purification of participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
- Subject ID, sample ID, and sample use variable obtained from participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
- Subject ID, disease diagnosis, age onset, and sex of participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type of cancer, and method for tumor and normal cell purification of participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
Similar models
Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type of cancer, and method for tumor and normal cell purification of participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
- Subject ID, sample ID, and sample use variable obtained from participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
- Subject ID, disease diagnosis, age onset, and sex of participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type of cancer, and method for tumor and normal cell purification of participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
C1299222 (UMLS CUI [1,2])
C1704788 (UMLS CUI [1,2])
C0007634 (UMLS CUI [1,3])
C0185115 (UMLS CUI [1,4])
C0012854 (UMLS CUI [1,5])
C0025663 (UMLS CUI [1,2])
C0027651 (UMLS CUI [1,3])
C1268443 (UMLS CUI [1,4])
C1998793 (UMLS CUI [1,5])
Aucun commentaire